Biofrontera Stock In The News

BFRI Stock  USD 0.93  0.01  1.06%   
Our overall analysis of Biofrontera's news coverage and content from conventional and social sources shows investors' bearish mood towards Biofrontera. The specific impact of Biofrontera news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Biofrontera's overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Biofrontera headlines in addition to utilizing other, more conventional financial analysis modules. Check out Biofrontera Backtesting and Biofrontera Hype Analysis.
For more detail on how to invest in Biofrontera Stock please use our How to Invest in Biofrontera guide.

Biofrontera Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
Biofrontera Inc. Announces Voting Results from 2022 Annual Meeting of Stockholders
https://www.globenewswire.com/news-release/2022/12/16/2575467/0/en/Biofrontera-Inc-Announces-Voting-Results-from-2022-Annual-Meeting-of-Stockholders.html
 Bullish
Yahoo News
11 Best German Stocks to Buy Now
https://finance.yahoo.com/news/11-best-german-stocks-buy-151835894.html
 Bullish
Macroaxis News: globenewswire.com
Biofrontera Inc. to Participate in Benchmark’s 11th Annual Discovery One-on-One Investor Conference
https://www.globenewswire.com/news-release/2022/11/30/2565369/0/en/Biofrontera-Inc-to-Participate-in-Benchmark-s-11th-Annual-Discovery-One-on-One-Investor-Conference.html
 Neutral
Macroaxis News: globenewswire.com
BIOFRONTERA INC. TO PARTICIPATE IN RENMA...
https://www.globenewswire.com/news-release/2022/11/28/2563362/0/en/BIOFRONTERA-INC-TO-PARTICIPATE-IN-RENMARK-S-VIRTUAL-NON-DEAL-ROADSHOW-SERIES-ON-WEDNESDAY-NOVEMBER-30-MONDAY-DECEMBER-5-FRIDAY-DECEMBER-9-AND-MONDAY-DECEMBER-19-2022.html
 Bullish
Macroaxis News: globenewswire.com
Biofrontera to Launch Phase 3 Clinical S...
https://www.globenewswire.com/news-release/2022/11/21/2559911/0/en/Biofrontera-to-Launch-Phase-3-Clinical-Study-Evaluating-Ameluz-PDT-for-the-Treatment-of-Actinic-Keratosis-on-the-Extremities-Neck-and-Trunk.html
 Neutral
Macroaxis News: globenewswire.com
Biofrontera Inc. Reports Third Quarter 2022 Financial Results and Provides a Business Update
https://www.globenewswire.com/news-release/2022/11/14/2555072/0/en/Biofrontera-Inc-Reports-Third-Quarter-2022-Financial-Results-and-Provides-a-Business-Update.html
 Bullish
Macroaxis News: globenewswire.com
Biofrontera Inc. to Report Third Quarter Financial Results on November 14, 2022
https://www.globenewswire.com/news-release/2022/11/10/2553576/0/en/Biofrontera-Inc-to-Report-Third-Quarter-Financial-Results-on-November-14-2022.html
 Neutral
Macroaxis News: globenewswire.com
Biofrontera Inc. Fully Exercises Recently Acquired Options to Purchase Shares of Biofrontera AG
https://www.globenewswire.com/news-release/2022/11/08/2551513/0/en/Biofrontera-Inc-Fully-Exercises-Recently-Acquired-Options-to-Purchase-Shares-of-Biofrontera-AG.html
 Bullish
Macroaxis News: globenewswire.com
Biofrontera Inc. Enters into Agreements to Purchase Options of Biofrontera AG
https://www.globenewswire.com/news-release/2022/10/31/2544628/0/en/Biofrontera-Inc-Enters-into-Agreements-to-Purchase-Options-of-Biofrontera-AG.html
 Bullish
Macroaxis News: globenewswire.com
Biofrontera Inc. Names Fred Leffler as Chief Financial Officer
https://www.globenewswire.com/news-release/2022/10/24/2539866/0/en/Biofrontera-Inc-Names-Fred-Leffler-as-Chief-Financial-Officer.html
 Neutral

Biofrontera Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Biofrontera and other traded companies coverage with news coverage. We help investors stay connected with Biofrontera headlines for the 15th of March 2025 to make an informed investment decision based on correlating the impacts of news items on Biofrontera Stock performance. Please note that trading solely based on the Biofrontera hype is not for everyone as timely availability and quick action are needed to avoid losses.
Biofrontera's linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Biofrontera investors visualize upcoming and past events in order to time the market based on Biofrontera noise-free hype analysis.
Biofrontera stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Biofrontera earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Biofrontera that are available to investors today. That information is available publicly through Biofrontera media outlets and privately through word of mouth or via Biofrontera internal channels. However, regardless of the origin, that massive amount of Biofrontera data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Biofrontera news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Biofrontera relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Biofrontera's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Biofrontera alpha.

Biofrontera Largest EPS Surprises

Earnings surprises can significantly impact Biofrontera's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2023-03-08
2022-12-31-0.11-0.14-0.0327 
2022-04-08
2022-03-31-0.18-0.150.0316 
2021-12-31
2021-12-31-0.18-0.150.0316 
2023-05-12
2023-03-31-0.19-0.28-0.0947 
2022-11-14
2022-09-30-0.29-0.110.1862 
2022-08-12
2022-06-30-0.34-0.050.2985 
View All Earnings Estimates

Biofrontera Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Biofrontera Stock. Current markets are strongly bullish. About 93% of major world exchanges and indexes are currently up. See today's market update for more information.
Gurufocus Stories at Macroaxis
11th of March 2025
Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21...
at gurufocus.com 
zacks News
27th of February 2025
Vericel Corporation Tops Q4 Earnings Estimates
at zacks.com 
news
7th of February 2025
Financial Review Biofrontera and Indaptus Therapeutics
at thelincolnianonline.com 
Gurufocus Stories at Macroaxis
8th of January 2025
Biofrontera Inc. Announces Achievement of Key Milestone In Phase
at gurufocus.com 
Yahoo News
23rd of December 2024
Biofrontera Inc. Announces 100 RhodoLED XL Machines Now Placed in US Market
at finance.yahoo.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Biofrontera in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Biofrontera's short interest history, or implied volatility extrapolated from Biofrontera options trading.
When determining whether Biofrontera offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biofrontera's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biofrontera Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biofrontera Stock:
Check out Biofrontera Backtesting and Biofrontera Hype Analysis.
For more detail on how to invest in Biofrontera Stock please use our How to Invest in Biofrontera guide.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biofrontera. If investors know Biofrontera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biofrontera listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
1.16
Revenue Per Share
8.497
Quarterly Revenue Growth
0.013
Return On Assets
(0.46)
Return On Equity
(3.91)
The market value of Biofrontera is measured differently than its book value, which is the value of Biofrontera that is recorded on the company's balance sheet. Investors also form their own opinion of Biofrontera's value that differs from its market value or its book value, called intrinsic value, which is Biofrontera's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biofrontera's market value can be influenced by many factors that don't directly affect Biofrontera's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biofrontera's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biofrontera is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biofrontera's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.